Join us today at 4:30 pm ET for our first quarter 2025 financial results via conference call and webcast: bit.ly/4jOaVsS $SAGE

We will present financial results for the first quarter of 2025 on Tuesday, April 29, 2025 at 4:30 PM ET via live webcast and conference call. Learn more: bit.ly/3EoSJXI $SAGE

We support @MMHLA2’s first-ever National #DayofAction for #MaternalMentalHealth. About 1 in 8 women report experiencing symptoms of #postpartumdepression, yet many lack support. Together, we can help drive lasting change by raising awareness and advocating for better care.

Join us today at 4:30 pm ET for our fourth quarter and full year 2024 financial results via conference call and webcast: bit.ly/4hVy1wX $SAGE

We will present financial results for the fourth quarter and full year of 2024 on Tuesday, February 11, 2025 at 4:30 PM ET via live webcast and conference call. Learn more: bit.ly/40z9RRG $SAGE

We look forward to our presentation at @jpmorgan Healthcare Conference on January 15 at 8:15 AM PST. Join the live webcast and hear about the year ahead: bit.ly/4gDxPlI #JPM25

On December 4th, join us for our fireside chat at the 2024 @Piper_Sandler Healthcare Conference. The #LIVE webcast begins streaming at 9:00 AM ET. Watch here: bit.ly/4i0cDan $SAGE

This week at @PsychCongress, Sage Therapeutics, in partnership with @NAMICommunicate and @Biogen, shared new insights into #postpartumdepression (PPD) and its impact on women and families. ​ We're proud to announce that our joint research poster focused on the burden of PPD has been selected as a #PsychCongress2024 poster award finalist, underscoring the importance of improving the standard of care for the #maternalmentalhealth community.​ Discover more about maternal mental health and resources through NAMI: bit.ly/3YKcDDZ

Join us today at 4:30 pm ET for our third quarter financial results via conference call and webcast: bit.ly/40kceJv $SAGE

The Sage team is excited to attend @PsychCongress this week. We look forward to connecting with industry leaders dedicated to improving the diagnosis and treatment of maternal mental health and postpartum depression (PPD).​ ​ Learn more here: bit.ly/40oZAZI #PsychCongress2024

Update: We will present third quarter financial results on October 29th, 2024 at 4:30 pm ET via live webcast and conference call. Learn more: bit.ly/48b7SXc $SAGE

Today, we announced topline results from our Phase 2 LIGHTWAVE study in the treatment of mild cognitive impairment in Alzheimer’s disease. Read more: bit.ly/3XV7ebK

We are incredibly honored to share that Sage Therapeutics, in collaboration with our partners at @biogen, has been named a winner for @PM360online's prestigious Trailblazer Award in the “Product Launch of the Year” category for our work in #PostpartumDepression.​ ​ Congratulations to all the finalists and winners, and a heartfelt thank you to @PM360online for an unforgettable evening. #PM360Trailblazers​ ​ Read more: prn.to/3Y9QzCi

This weekend, the Sage team will be attending @EHDN_News & Enroll-HD 2024 in France. We look forward to sharing our #HuntingtonsDisease (HD) research, including an overview of our HD clinical studies. #EHDN2024

Join us today at 4:30 pm ET for our second quarter financial results via conference call and webcast: bit.ly/3zUp0Dv $SAGE

With our partner, @Biogen, today we announced topline results from the KINETIC 2 Study in Essential Tremor. Read more: investor.sagerx.com/news-rel…

Update: We will present second quarter financial results on Wednesday, July 31st, 2024 at 4:30 pm ET via live webcast and conference call. Learn more: bit.ly/4bKN0WR $SAGE

We are proud to share that Matt Lasmanis, Sage's Chief Technology and Innovation Officer, has been named to @constellationr's #BT150 list! Learn more: bit.ly/4b3B5Dc

This morning, we provided an update on our #HuntingtonsDisease program. Read the latest news here: bit.ly/4egp7ZQ

We're looking forward to attending @GoldmanSachs 45th Annual Global Healthcare Conference on June 12th. Join us for a fireside chat at 2:00 pm ET here: bit.ly/4cbtTpJ